First Trust Advisors
LOGC

First Trust Advisors’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

First Trust Advisors’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-13,110
Closed -$111K – 2531
2020
Q2 		$111K Buy
13,110
+1,148
+10% +$7.55K ﹤0.01% 2322
2020
Q1 		$59K Sell
11,962
-2,319
-16% -$18K ﹤0.01% 2318
2019
Q4 		$103K Sell
14,281
-118
-0.8% -$1.07K ﹤0.01% 2361
2019
Q3 		$156K Buy
+14,399
New +$154K ﹤0.01% 2351

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

First Trust Advisors's LOGC Position: Q3 2020 in Review

First Trust Advisors sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q3 2020, closing a stake of 13,110 shares — an estimated $111K sold.

First Trust Advisors first reported a position in LOGC in Q3 2019 and held it in 4 quarters. The position peaked at $156K in Q3 2019. 51 funds tracked by Wall St. Rank hold LOGC as of Q3 2020.

  • First Trust Advisors reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • First Trust Advisors sold 13,110 LogicBio Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $111K.
  • First Trust Advisors first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q3 2019 and held it in 4 quarters.
  • First Trust Advisors's LogicBio Therapeutics, Inc. Common Stock position peaked at $156K in Q3 2019.
  • 51 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q3 2020.

Based on First Trust Advisors's 13F filing for Q3 2020, filed 5 Nov 2020.